newsfilter
← Latest News
Business Wire·

Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results

Dosed first patient with nulabeglogene autogedtemcel (nula-cel), formerly known as GPH101, in Phase 1/2 CEDAR clinical trial in people with sickle cell disease; initial proof-of-concept data now anticipated in mid-2023 Presented preclinical gene repl